Pfizer's strong drug pipeline signals growth potential beyond current analyst expectations.

Pfizer is developing a strong mid- and late-stage drug pipeline, including promising candidates like atirmociclib, tilrekimig, Padcev, and a Lyme disease vaccine. The obesity drug PF'3944 is advancing quickly with 10 phase 3 trials and encouraging phase 2 results for monthly dosing. Additionally, Pfizer may gain over $10 billion in extended revenue from tafamidis patent litigation. These developments suggest Pfizer is positioned for growth later this decade, which is not yet fully recognized by analysts.